APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers

dc.contributor.authorBurwick, R. M.por
dc.contributor.authorRamsay, P. P.por
dc.contributor.authorHaines, J. L.por
dc.contributor.authorHauser, S. L.por
dc.contributor.authorOksenberg, J. R.por
dc.contributor.authorPericak-Vance, M. A.por
dc.contributor.authorSchmidt, S.por
dc.contributor.authorCompston, A.por
dc.contributor.authorMaciel, P.por
dc.contributor.authorSantos, Monicapor
dc.contributor.other[et al.]
dc.date.accessioned2020-10-30T14:48:33Z
dc.date.embargo10000-01-01
dc.date.issued2006-05-09
dc.description.abstractBackground: Previous studies have examined the role of APOE variation in multiple sclerosis (MS), but have lacked the statistical power to detect modest genetic influences on risk and disease severity. The meta- and pooled analyses presented here utilize the largest collection, to date, of MS cases, controls, and families genotyped for the APOE epsilon polymorphism. Methods: Studies of MS and APOE were identified by searches of PubMed, Biosis, Web of Science, Cochrane Review, and Embase. When possible, authors were contacted for individual genotype data. Meta-analyses of MS case-control data and family-based analyses were performed to assess the association of APOE epsilon genotype with disease risk. Pooled analyses of MS cases were also performed to assess the influence of APOE epsilon genotype on disease severity. Results: A total of 22 studies (3,299 MS cases and 2,532 controls) were available for meta-analysis. No effect of ε2 or ε4 status on MS risk was observed (summary OR 1.14, 95% CI 0.96 –1.34 and OR 0.89, 95% CI 0.78 –1.01). Results obtained from analyses of APOE genotypes in 1,279 MS families were also negative (p 0.61). Finally, results from pooled analyses of 4,048 MS cases also argue strongly that APOE epsilon status does not distinguish a relapsing-remitting from primary progressive disease course, or influence disease severity, as measured by the Expanded Disability Status Scale and disease duration. Conclusion: Overall, these findings do not support a role for APOE in multiple sclerosis, and underscore the importance of using large sample sizes to detect modest genetic effects, particularly in studies of genotypephenotype relationships.por
dc.distributioninternationalpor
dc.identifier.doi10.1212/01.wnl.0000210531.19498.3fpor
dc.identifier.eissn1526-632X
dc.identifier.issn0028-3878
dc.identifier.pmid16682670por
dc.identifier.urihttps://hdl.handle.net/1822/67930
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherAmerican Academy of Neurology (AAN)por
dc.rightsrestrictedAccesspor
dc.subjectAllelespor
dc.subjectApolipoprotein E2por
dc.subjectApolipoprotein E4por
dc.subjectApolipoproteins Epor
dc.subjectCase-Control Studiespor
dc.subjectGenetic Predisposition to Diseasepor
dc.subjectGenotypepor
dc.subjectHumanspor
dc.subjectLinkage Disequilibriumpor
dc.subjectMultiple Sclerosispor
dc.subjectPedigreepor
dc.subjectPhenotypepor
dc.subjectPolymorphism, Geneticpor
dc.subjectPolymorphism, Single Nucleotidepor
dc.subjectRiskpor
dc.subjectSeverity of Illness Indexpor
dc.subject.wosScience & Technologypor
dc.titleAPOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answerspor
dc.typearticlepor
dspace.entity.typePublicationen
oaire.citationEndPage1383por
oaire.citationIssue9por
oaire.citationStartPage1373por
oaire.citationVolume66por
sdum.journalNeurologypor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
burwick2006.pdf
Tamanho:
595.18 KB
Formato:
Adobe Portable Document Format